Allarity Therapeutics (NASDAQ:ALLR) Price Target Raised to $9.50 at Ascendiant Capital Markets

Allarity Therapeutics (NASDAQ:ALLR) had its target price increased by Ascendiant Capital Markets from $9.25 to $9.50 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

ALLR has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised Allarity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Allarity Therapeutics presently has an average rating of “Hold” and a consensus price target of $9.50.

Allarity Therapeutics Trading Down 1.7%

ALLR opened at $1.14 on Tuesday. The company has a market cap of $18.01 million, a P/E ratio of -1.93 and a beta of 0.23. The company’s 50 day moving average is $1.34 and its 200-day moving average is $1.22. Allarity Therapeutics has a 1-year low of $0.61 and a 1-year high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. On average, equities analysts forecast that Allarity Therapeutics will post -78.08 EPS for the current year.

Institutional Trading of Allarity Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Private Advisor Group LLC bought a new position in Allarity Therapeutics during the 3rd quarter worth $441,000. Citadel Advisors LLC acquired a new stake in shares of Allarity Therapeutics in the third quarter valued at about $149,000. XTX Topco Ltd bought a new position in shares of Allarity Therapeutics during the second quarter worth about $51,000. Geode Capital Management LLC raised its position in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock worth $51,000 after acquiring an additional 16,729 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Allarity Therapeutics in the second quarter worth approximately $27,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.